All In MedTech

FDA Clearance Tracker · P860047-S033

OcuCoat OVD

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 17, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 17, 2017

Approved

Time to decision

86 days

Received Nov 23, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P860047-S033
Device name
OcuCoat OVD
Applicant location
Irvine, CA
Received
Nov 23, 2016
Decided
Feb 17, 2017
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P860047

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

Approval for the addition of a cannula retention clip to be packaged with both the Amvisc and Amvisc Plus sodium hyaluronate (NaHy) solutions.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.